Fulcrum Therapeutics (FULC)
(Delayed Data from NSDQ)
$8.60 USD
+0.60 (7.50%)
Updated Jul 22, 2024 04:00 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Earnings News For FULC
-
Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Tops Revenue Estimates
-
Fulcrum Therapeutics, Inc. (FULC) Reports Q2 Loss, Lags Revenue Estimates
-
Fulcrum Therapeutics, Inc. (FULC) Reports Q1 Loss, Misses Revenue Estimates
-
Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Misses Revenue Estimates
-
Fulcrum Therapeutics, Inc. (FULC) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
-
Fulcrum Therapeutics, Inc. (FULC) Reports Q3 Loss, Lags Revenue Estimates
-
Fulcrum Therapeutics, Inc. (FULC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
-
Fulcrum Therapeutics, Inc. (FULC) Reports Q2 Loss, Lags Revenue Estimates
-
Fulcrum Therapeutics, Inc. (FULC) Reports Q1 Loss, Misses Revenue Estimates
-
Earnings Preview: Fulcrum Therapeutics, Inc. (FULC) Q1 Earnings Expected to Decline
-
Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Tops Revenue Estimates
-
Fulcrum Therapeutics, Inc. (FULC) Reports Q3 Loss, Tops Revenue Estimates
-
Fulcrum Therapeutics, Inc. (FULC) Reports Q2 Loss, Tops Revenue Estimates
-
Will Fulcrum Therapeutics, Inc. (FULC) Report Negative Q2 Earnings? What You Should Know
-
Fulcrum Therapeutics, Inc. (FULC) Reports Q1 Loss, Tops Revenue Estimates
-
Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Tops Revenue Estimates